Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPHINASDAQ:INKTNASDAQ:KZRNYSE:NNVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$1.67+4.4%$7.62$1.20▼$3.35$5.42M0.8564,611 shs40,355 shsINKTMiNK Therapeutics$7.18+2.1%$7.73$4.56▼$13.79$28.60M0.1612,222 shs4,664 shsKZRKezar Life Sciences$4.34+3.9%$4.27$3.62▼$9.18$31.60M0.6156,654 shs8,954 shsNNVCNanoViricides$1.54+1.0%$1.32$0.94▼$3.59$24.67M0.95253,072 shs109,999 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma0.00%-27.93%-16.23%-91.79%-94.59%INKTMiNK Therapeutics0.00%-1.63%-9.34%-20.59%-28.04%KZRKezar Life Sciences0.00%+6.11%-7.33%-26.84%-39.91%NNVCNanoViricides0.00%-15.08%+16.92%+27.73%-36.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHIChina PharmaN/AN/AN/AN/AN/AN/AN/AN/AINKTMiNK Therapeutics3.0509 of 5 stars3.54.00.00.03.31.70.6KZRKezar Life Sciences4.5057 of 5 stars3.25.00.04.62.92.50.6NNVCNanoViricidesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHIChina Pharma 0.00N/AN/AN/AINKTMiNK Therapeutics 3.00Buy$37.50422.65% UpsideKZRKezar Life Sciences 2.33Hold$39.50809.30% UpsideNNVCNanoViricides 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CPHI, NNVC, KZR, and INKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHIChina Pharma$4.30M1.27N/AN/A$0.70 per share2.39INKTMiNK TherapeuticsN/AN/AN/AN/A($5.23) per shareN/AKZRKezar Life Sciences$7M4.53N/AN/A$25.80 per share0.17NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/AINKTMiNK Therapeutics-$22.46M-$2.52N/AN/AN/AN/AN/A-189.14%8/12/2025 (Estimated)KZRKezar Life Sciences-$101.87M-$10.82N/AN/AN/AN/A-54.95%-46.11%8/12/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ALatest CPHI, NNVC, KZR, and INKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A3/25/2025Q4 2024 & Study ResultKZRKezar Life Sciences-$2.71-$2.77-$0.06-$2.77N/AN/A3/18/2025Q4 2024INKTMiNK Therapeutics-$0.50-$0.62-$0.12-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHIChina PharmaN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHIChina Pharma0.220.790.26INKTMiNK TherapeuticsN/A0.890.89KZRKezar Life Sciences0.057.657.65NNVCNanoViricidesN/A3.442.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHIChina PharmaN/AINKTMiNK Therapeutics2.87%KZRKezar Life Sciences67.90%NNVCNanoViricides10.30%Insider OwnershipCompanyInsider OwnershipCPHIChina Pharma17.32%INKTMiNK Therapeutics22.48%KZRKezar Life Sciences10.40%NNVCNanoViricides4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableINKTMiNK Therapeutics303.99 million3.15 millionNo DataKZRKezar Life Sciences607.31 million6.62 millionNot OptionableNNVCNanoViricides2016.07 million14.92 millionOptionableCPHI, NNVC, KZR, and INKT HeadlinesRecent News About These CompaniesNanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025May 28, 2025 | accessnewswire.comNanoViricides president backs FDA's targeted COVID booster policy shiftMay 22, 2025 | proactiveinvestors.comThe New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides’ Dr. DiwanMay 22, 2025 | miamiherald.comThe New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. DiwanMay 22, 2025 | accessnewswire.comNanoViricides advances NV-387 antiviral program, eyes Phase II trials for MpoxMay 16, 2025 | proactiveinvestors.comMeasles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the SolutionMay 15, 2025 | star-telegram.comNanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the SolutionMay 15, 2025 | finanznachrichten.deNanoViricides progresses antiviral portfolio as measles and MPox threats riseMay 14, 2025 | proactiveinvestors.comNanoViricides wins ethics approval for Phase II Mpox drug trial in DRCMay 8, 2025 | proactiveinvestors.comNanoViricides, Inc. Announces Participation in the D. ...May 5, 2025 | gurufocus.comNanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYCMay 5, 2025 | newsfilecorp.comNanoViricides advances measles drug development amid rising US casesApril 29, 2025 | proactiveinvestors.comMeasles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat ItApril 29, 2025 | accessnewswire.comNanoViricides evaluating antiviral drug NV-387 for measles treatmentApril 14, 2025 | proactiveinvestors.comMeasles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the OutbreakApril 14, 2025 | accessnewswire.comNanoViricides unaffected by US tariff turmoil, says CFOApril 5, 2025 | proactiveinvestors.comNanoViricides eyes role in US bird flu fight as USDA unveils $100M initiativeMarch 28, 2025 | proactiveinvestors.comNanoViricides says business unaffected by US tariffs, highlights antiviral pipelineMarch 11, 2025 | proactiveinvestors.comNanoViricides says business unaffected by US tariffs, highlights antiviral pipelineMarch 11, 2025 | proactiveinvestors.comNanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the CompanyMarch 11, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPHI, NNVC, KZR, and INKT Company DescriptionsChina Pharma NYSE:CPHI$1.67 +0.07 (+4.38%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.MiNK Therapeutics NASDAQ:INKT$7.18 +0.15 (+2.06%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Kezar Life Sciences NASDAQ:KZR$4.34 +0.16 (+3.92%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.NanoViricides NYSE:NNVC$1.54 +0.02 (+0.99%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
